Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study.
Julie E ManginoMichael S FirstenbergRita K C MilewskiWilliam Rhys-WilliamsJames P LeesAaron DaneWilliam G LoveJesus Gonzalez MorenoPublished in: Infection control and hospital epidemiology (2023)
We studied 83 cardiac-surgery patients with nasal S. aureus carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a S. aureus nasal carriage reduction of 2.5 log 10 with XF-73 compared to 0.4 log 10 CFU/mL for those who received placebo (95% CI, -2.7 to -1.5; P < .0001).
Keyphrases
- cardiac surgery
- end stage renal disease
- minimally invasive
- staphylococcus aureus
- coronary artery bypass
- placebo controlled
- newly diagnosed
- chronic kidney disease
- ejection fraction
- double blind
- prognostic factors
- acute kidney injury
- peritoneal dialysis
- clinical trial
- escherichia coli
- coronary artery disease
- study protocol
- pseudomonas aeruginosa
- phase iii
- acute coronary syndrome
- open label